Orchid Pharma Ltd - 524372 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst/ Investor Earning Call.08-08-2023
Orchid Pharma Ltd - 524372 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst/ Investor Earning Call.Orchid Pharma Ltd - 524372 - Board Meeting Intimation for To Consider And Approve Un-Audited Financial Result (Standalone And Consolidated) For The Quarter Ended June 30, 2023.
Orchid Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2023 ,inter alia, to consider and approve Orchid Pharma Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2023 ,inter alia, to consider and approve Un-Audited Financial Result (Standalone and Consolidated) for the quarter ended June 30, 2023.Orchid Pharma Ltd - 524372 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Advertisement.Orchid Pharma seeks shareholder nod for Otsuka Chemicals
Orchid Pharma filed the notice of its 30th annual general meeting to be held on August 9Orchid Pharma Ltd - 524372 - Business Responsibility and Sustainability Reporting (BRSR)
Business Responsibility and Sustainability Reporting 2022-23Orchid Pharma Ltd - 524372 - Notice Of 30Th Annual General Meeting
Notice of 30th Annual General MeetingOrchid Pharma Ltd - 524372 - Reg. 34 (1) Annual Report.
Integrated Annual Report for the Financial Year 2022-23Orchid Pharma Ltd - 524372 - Intimation Of The 30Th Annual General Meeting Of The Company
Intimation of the 30th Annual General Meeting of the Company.Orchid Pharma shares hit fresh high after signing tech transfer pact for cephalosporin intermediate
A technology transfer agreement is made for a fermentation-based 7ACA project' under the production-linked incentive (PLI) schemeOrchid Pharma Ltd - 524372 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Compliance Certificate under Regulation 74(5) of SEBI (DP) Regulation, 2018 for the quarter ended June 30, 2023.